SGCA
ALXN

Steel Grove Capital Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Steel Grove Capital Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-8,650
Closed -$842K – 302
2018
Q4 		$842K Sell
8,650
-597
-6% -$70.6K 0.12% 152
2018
Q3 		$1.28M Hold
9,247
– – 0.18% 110
2018
Q2 		$1.15M Hold
9,247
– – 0.18% 113
2018
Q1 		$1.03M Buy
9,247
+5,762
+165% +$689K 0.16% 128
2017
Q4 		$417K Hold
3,485
– – 0.06% 216
2017
Q3 		$489K Buy
+3,485
New +$473K 0.09% 169

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Steel Grove Capital Advisors's ALXN Position: Q1 2019 in Review

Steel Grove Capital Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 8,650 shares — an estimated $842K sold.

Steel Grove Capital Advisors first reported a position in ALXN in Q3 2017 and held it in 6 quarters. The position peaked at $1.28M in Q3 2018. 612 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • Steel Grove Capital Advisors reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Steel Grove Capital Advisors sold 8,650 Alexion Pharmaceuticals shares in Q1 2019, an estimated $842K.
  • Steel Grove Capital Advisors first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 6 quarters.
  • Steel Grove Capital Advisors's Alexion Pharmaceuticals position peaked at $1.28M in Q3 2018.
  • 612 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Steel Grove Capital Advisors's 13F filing for Q1 2019, filed 14 May 2019.